Eight stories could define the year for biotech investors


By most measures, biotech investors shouldn't have many gripes about the first half of 2017. The go-go years of 2013 and 2014 aren't making a roaring comeback, but our little corner of Wall Street has outperformed the broader market, despite the constant threat of D.C. meddling.



from Biotech News